Multivariate analysis of fold-change in the up-/down-regulated expression ratio
| Significant predictors* . | % of cases . | Fold change . | P . |
|---|---|---|---|
| Interphase FISH-defined amp1q21 | 43 | 0.316 | < .001 |
| Cytogenetic abnormalities | 30 | 0.353 | < .001 |
| CCND1 or CCND3 spike | 20 | −0.248 | .008 |
| MAF/MAFB spike | 4 | 0.430 | .030 |
| MMSET/FGFR3 spike | 14 | 0.297 | .005 |
| LDH, 190 U/L or more | 31 | 0.332 | < .001 |
| Albumin, 35 g/L or less | 18 | 0.249 | .014 |
| Significant predictors* . | % of cases . | Fold change . | P . |
|---|---|---|---|
| Interphase FISH-defined amp1q21 | 43 | 0.316 | < .001 |
| Cytogenetic abnormalities | 30 | 0.353 | < .001 |
| CCND1 or CCND3 spike | 20 | −0.248 | .008 |
| MAF/MAFB spike | 4 | 0.430 | .030 |
| MMSET/FGFR3 spike | 14 | 0.297 | .005 |
| LDH, 190 U/L or more | 31 | 0.332 | < .001 |
| Albumin, 35 g/L or less | 18 | 0.249 | .014 |
N = 250; R2 = 0.324. Of the 351 patients, 98 were missing amp1q21 by FISH, and an additional 3 were missing albumin.
Predictors with P > .05 for both outcomes: age ≥ 65 years, β2-microglobulin (≥ 297.5 nM to ≥ 467.5 nM), C-reactive protein (≥ 4 mg/L).